Combination therapy for Type 2 diabetes: Repaglinide plus rosiglitazone

Diabetic Medicine

Volumn 21, Issue 4, 2004, Pages 329-335

  Raskin, P ^a   McGill, J ^b   Saad, M F ^c   Cappleman, J M ^d   Kaye, W ^e   Khutoryansky, N ^f   Hale, P M ^f  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c Los Angeles Diabetes Center   (United States)

^d Primary Care Specialists   (United States)

^e Metabolic Research Institute Inc   (United States)

^f NOVO NORDISK INC   (United States)

Author keywords

Insulin secretagogue; Lipids; Oral antidiabetic drug; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATORVASTATIN; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; REPAGLINIDE; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES CONTROL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PAIN; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINUSITIS; TOOTH DISEASE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; WEIGHT GAIN;

BLOOD GLUCOSE; CARBAMATES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PIPERIDINES; THIAZOLIDINEDIONES; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 1942487714     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01143.x     Document Type: Article

References (16)

1. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2002; 25: S28-S32.
2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
4. Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician 2001; 63: 1747-1756.
5. Repaglinide (Prandin®) product labeling. In Physicians' Desk Reference, 56th edn. Montvale, NJ: Medical Economics Co., Inc., 2002; 2432-2435.
6. Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22: 119-124.
7. Raskin P, Jovanovic L, Berger S, Schwartz S, Woo V, Ratner B. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes. Diabetes Care 2000; 23: 979-983.
8. Center for Drug Evaluation and Research. Draft Guidance, Evaluation of New Treatments for Diabetes Mellitus. Rockville, MD: Federal Drug Administration, Division of Metabolism and Endocrine Drug Products, 1997.
9. Khutoryansky NM, Chernick MR. Incremental Methods of Imputation in Longitudinal Clinical Trials. Joint Statistical Meetings Proceedings. New York: American Statistical Association, 2002; 1819-1823.
10. Strange P, Schwartz SL, Graf RJ, Polvino W, Weston I, Marbury TC et al. Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes. Diabetes Technol Ther 1999; 1: 247-256.
11. Rosiglitazone (Avandia®) product labeling. In Physicians' Desk Reference, 56th edn. Montvale, NJ: Medical Economics Co., Inc., 2002; 1490-1494.
12. Betteridge DJ. Dyslipidaemia and diabetes. Pract Diabetes Int 2001; 18: 201-207.
13. Erkelens DW. Insulin resistance syndrome and type 2 diabetes mellitus. Am J Cardiol 2001; 88: 38J-42J.
14. Rubin CJ, Meneghini L, Pans M, Fiedorek FT. Glipizide/metformin tablets as second-line therapy in type 2 diabetes: efficacy, safety, and tolerability. Diabetes 2002; 51 (Abstract 458-P, Suppl. 2): A113.
15. Damsbo P, Clauson P, Marbury T, Windfeld K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetes patients. Diabetes Care 1999; 22: 789-794.
16. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 2001; 52: 239-257.